Team
A leading management team, backed by proven scientific founders.
Executive team
Scientific co-founders
We have a rich toolkit for editing the genome and transcriptome, but an equivalent framework for the proteome has remained elusive. UbiquiTx has built an AI-native platform for programmable modulation of the proteome — turning any protein target into one we can precisely modulate, not just knock out.
A single, modular construct: an AI-designed guide peptide, joined by a flexible linker to a swappable effector enzyme.
No binding pocket required. Guide peptides engage flat, non-conformational surfaces that PROTACs and molecular glues can't reach.
Swap the effector to degrade, stabilize, or relocalize the same target — not degradation alone.
Binding and function happen in the same step, so every hit from a screen is a functional one — nothing to validate twice.
Multiplexed peptide screening finds the best binders first. Combinatorial CLIP assembly then turns those winners into a functional cellular outcome — degraded, stabilized, or relocalized.
Multiple protein language models generate and rank candidates — not hand-engineered guesses.
Every cycle produces both binding and functional readouts — proprietary data no public database has.
Design–screen–measure–learn compounds — every round sharpens the next, across every program.
Delivers in-cell, mechanism-matched modulation of a nominated target, with dose-response, kinetics, and PTM/isoform selectivity — before partners commit capital.
Delivers a mechanism-matched go/no-go on a nominated target by addressing a protein directly.
Sequence-level and permanent. Powerful for somatic targets, but acts on the gene.
Knockdown only. Transient, with limited tissue reach.
A pipeline in oncology and regenerative disease, advancing on non-dilutive funding alongside the validation business rather than competing with it for capital.
For partnership, licensing, and investment inquiries, we'd be glad to talk.
accounts@ubiquitx.com
